<DOC>
	<DOCNO>NCT00824473</DOCNO>
	<brief_summary>The purpose study determine one allergy medication ( 0.15 % azelastine hydrochloride ) effective Placebo alone</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Nasal Spray Treat Seasonal Allergies</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>1 . Male female subject 12 year age old 2 . Provide write informed consent/pediatric assent . If subject minor , parent legal guardian must give write informed consent 3 . Screening Visit : Have 12hour reflective TNSS least 8 possible 12 congestion score 2 3 visit 1 4 . Randomization Visit : Have 12hour reflective TNSS ( AM PM ) least 8 3 separate symptom assessment ( one within 2 day visit 2 , include morning visit 2 ) Leadin Period . In addition , AM PM 12hour reflective nasal congestion score 2 3 must record 3 separate symptom assessment ( one within 2 day visit 2 , include morning visit 2 ) 5 . Willing able comply study requirement 6 . At least 2year history SAR Texas Mountain Cedar season 7 . The presence IgEmediated hypersensitivity Texas Mountain Cedar , confirm positive response skin prick within last year . A positive response define wheal diameter least 3 mm large negative control . 8 . General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer . When doubt , investigator confer sponsor 's medical monitor designee determine eligibility study . 9 . Subjects receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) .Dose reduction new bottle use preclude participation . 10 . Subjects currently receive sublingual immunotherapy exclude . A 6month washout period require follow last dose sublingual immunotherapy . 1 . On Focused Nasal Examination , presence superficial moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation ( Grade 1b4 ) either screen visit randomization visit disqualify subject study . 2 . Other nasal disease ( ) likely affect deposition intranasal medication , sinusitis , rhinitis medicamentosa , clinically significant polyposis , clinically significant nasal structural abnormality . 3 . Nasal surgery sinus surgery within previous year . 4 . Chronic sinusitis 3 episode per year 5 . Planned travel outside study area study period 6 . The use investigational drug within 30 day prior visit 1 . No investigational product permit use conduct study 7 . Presence hypersensitivity drug similar azelastine either sorbitol sucralose ( SplendaÂ® brand sweetener ) 8 . Women pregnant nursing 9 . Women childbearing potential abstinent practice medically acceptable method contraception 10 . Respiratory Tract Infections within 14 day prior visit 1 11 . Respiratory Tract Infections require antibiotic treatment 14 day prior visit 1 12 . Asthma ( exception intermittent asthma ) . Subjects mild , intermittent asthma require shortacting inhaled bronchodilator ( often twice per week ) nocturnal awaken result asthma eligible enrollment 13 . Significant pulmonary disease include COPD 14 . Clinically significant arrhythmia symptomatic cardiac condition 15 . A known history alcohol drug abuse within last 2 year 16 . Existence surgical medical condition physical laboratory finding , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug ; might significantly affect subject 's ability complete trial ; safety trial . 17 . Clinically relevant abnormal physical finding within 1 week randomization , opinion investigator , would interfere objective study may preclude compliance study procedures 18 . Participation MedPointe Protocols MP439 MP440 . 19 . Employees research center / private practice family exclude</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>